Lataa...
Long-acting preparations of exenatide
Exenatide has been widely used for the treatment of type 2 diabetes mellitus. However, its short plasma half-life of 2.4 hours has limited its clinical application. The exenatide products on the market, twice-daily Byetta™ and once-weekly Bydureon™ (both Amylin Pharmaceuticals, San Diego, CA, USA),...
Tallennettuna:
| Päätekijät: | , , , , , , |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Dove Medical Press
2013
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3771853/ https://ncbi.nlm.nih.gov/pubmed/24039406 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S46970 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|